AbstractA newly introduced diazo reagent, 1‐diazo‐N,N‐bis(4‐methoxybenzyl)methanesulfonamide, enables access to a range of azole‐based primary sulfonamides via [3+2] cycloaddition followed by protecting group removal. Such compounds are representative of the sulfonamide chemical space highly relevant but hitherto not investigated in the context of inhibition of therapeutically relevant isoforms of carbonic anhydrase enzyme. Using this reagent, three sets of primary sulfonamides based on pyrazole, 1,2,3‐triazole and tetrazole cores were synthesized and profiled for inhibition of tumor‐associated hCA IX and XII isoforms as well as abundant cytosolic hCA I and II isoforms. Using virtual library design and docking prioritization tool of the Schrödinger suite, one of the promising leads was evolved into a dual hCA IX/XII inhibitor with excellent selectivity over off‐target hCA I and II. The new synthetic strategy to access azole‐based primary sulfonamides will support the discovery of novel, isoform‐selective inhibitors of carbonic anhydrase within the poorly explored azole chemical space.
摘要 一种新引入的重氮试剂--1-重氮-N,N-双(4-甲氧基苄基)甲磺酰胺,能够通过[3+2]环加成法,然后去除保护基团,获得一系列唑基一级磺酰胺。此类化合物是磺酰胺化学领域的代表,具有很高的相关性,但迄今为止还没有在抑制治疗相关的碳酸酐酶异构体方面进行过研究。利用这种试剂,合成了三组以吡唑、1,2,3-三唑和四唑为核心的初级磺酰胺,并分析了它们对肿瘤相关的 hCA IX 和 XII 异构体以及丰富的细胞质 hCA I 和 II 异构体的抑制作用。利用薛定谔套件的虚拟库设计和对接优先排序工具,其中一个有前景的先导化合物发展成了对脱靶 hCA I 和 II 具有极佳选择性的 hCA IX/XII 双抑制剂。这一新的合成策略可以获得基于唑的伯氨基磺酰胺,有助于在探索不足的唑化学领域发现新型碳酸酐酶同工酶选择性抑制剂。